Mitochondrial Derived Peptides: Metabolic Gene Regulation via MOTS-c and Humanin

Executive Summary

Mitochondrial-derived peptides (MDPs) represent a recently recognised class of bioactive microproteins that are encoded by short open-reading frames within the mitochondrial genome. 

Unlike nuclear-encoded peptides, MDPs originate from mitochondrial DNA and function as retrograde signalling molecules that communicate metabolic status from mitochondria to the nucleus. Among the identified MDPs, Humanin and MOTS-c have emerged as critical regulators of metabolic homeostasis, insulin sensitivity, and stress responses. For research facilities investigating metabolic disease, ageing, and mitochondrial biology, understanding their distinct mechanisms of action and analytical considerations is essential.

1. Origins and Genetic Encoding

MDPs are encoded by short open-reading frames (sORFs) within the 16,569-nucleotide human mitochondrial genome. Three families have been identified: Humanin (HN), MOTS-c, and small Humanin-like peptides (SHLP1-6).

The genetic origins differ fundamentally. MOTS-c is encoded within the 12S ribosomal RNA gene (MT-RNR1), yielding a 16-amino-acid peptide with a molecular mass of approximately 2,175 Da. Humanin is encoded within the 16S ribosomal RNA gene (MT-RNR2) and exists as a 21- or 24-amino-acid peptide. Notably, the mitochondrial genetic code differs from nuclear DNA: ATA and ATT serve as start codons, AGA and AGG function as stop codons, and UGA codes for tryptophan rather than serving as a stop signal.

An important distinction for researchers: Humanin has nuclear-mitochondrial DNA segments (NUMTs)—nuclear copies that can complicate genomic analysis—whereas no NUMT-derived variants of MOTS-c have been identified.

2. Metabolic Gene Regulation Mechanisms

Both peptides regulate metabolic gene expression through distinct but complementary mechanisms.

MOTS-c functions as a metabolic stress-responsive retrograde signal. Under metabolic stress, it translocates to the nucleus and binds antioxidant response elements (ARE) in promoter regions, regulating gene expression in an NFE2L2/NRF2-dependent manner. Its primary metabolic action involves inhibition of the folate cycle, which reduces de novo purine biosynthesis, leading to accumulation of AICAR and activation of AMPK—the master regulator of cellular energy homeostasis. This AMPK activation promotes glucose clearance, lipid oxidation, and mitochondrial biogenesis. MOTS-c also activates mTORC2, promoting AKT phosphorylation and FOXO1 inhibition, which reduces myostatin expression and supports skeletal muscle growth.

Humanin operates primarily through cytoprotective and anti-apoptotic pathways. It interacts with BAX to inhibit apoptosis and activates chaperone-mediated autophagy. In metabolic contexts, human insulin promotes mitochondrial biogenesis, stimulates insulin secretion in pancreatic β-cells, and improves insulin signalling in hepatocytes. It also reduces lipid accumulation and lipogenic gene expression. Humanin exerts these effects through receptor-mediated signalling involving the tripartite complex of CNTFR-α/gp130/WSX-1, distinguishing it from MOTS-c's intracellular nuclear actions.

3. Physiological and Disease Associations

Circulating MDP levels correlate with metabolic health status. MOTS-c plasma levels decline with age (significantly lower in older vs. young subjects, P<0.001) and are reduced in obesity, insulin resistance, type 2 diabetes, and chronic kidney disease. Exercise substantially raises endogenous MOTS-c levels in skeletal muscle and circulation, indicating interorgan mitochondrial communication.

Humans exhibit more complex patterns. Circulating levels are decreased in impaired fasting glucose, type 2 diabetes, and endothelial dysfunction, yet increased in skeletal muscle of obese individuals and MELAS patients—possibly a tissue-specific compensatory response to energy deficiency. Humanin levels also respond to exercise modality: resistance training increased skeletal muscle humanin content by approximately 35% in prediabetic men, while Nordic walking showed no such change.

4. Analytical Considerations for Research Facilities

Working with MDPs presents unique analytical challenges. Circulating concentrations are often picomolar, requiring highly sensitive detection methods. ELISA is commonly employed for biofluid quantification, though cross-reactivity concerns exist.

For synthetic peptide characterisation, MOTS-c requires particular attention due to oxidation-sensitive residues. Its sequence contains methionine and tryptophan, making it susceptible to oxidation during synthesis and storage. Cleavage cocktails should include scavengers such as TIPS, water, and EDT, and antioxidant additives are recommended. RP-HPLC with a C18 stationary phase and acetonitrile/water gradients containing 0.1% TFA is standard for purification, achieving >98% purity. Mass spectrometry confirmation should verify the theoretical monoisotopic mass of approximately 2,174.4 Da.

Reconstitution protocols demand care: avoid mechanical agitation to prevent aggregation, and consider initial dissolution in minimal sterile acetic acid or DMSO before dilution into physiological buffers. Lyophilised peptide should be stored at -20°C or -80°C, and reconstituted aliquots should avoid repeated freeze-thaw cycles.

For research facilities seeking reference standards or further technical resources on MDPs, additional information is available through specialised peptide suppliers and mitochondrial research consortia.